Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Roboz, Gail J, Montesinos, Pau, Selleslag, Dominik, Wei, Andrew, Jang, Jun-Ho, Falantes, Jose, Voso, Maria T, Sayar, Hamid, Porkka, Kimmo, Marlton, Paula, Almeida, Antonio, Mohan, Sanjay, Ravandi, Farhad, Garcia-Manero, Guillermo, Skikne, Barry, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2016
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684733/
https://www.ncbi.nlm.nih.gov/pubmed/26785287
http://dx.doi.org/10.2217/fon.15.326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684733/
https://www.ncbi.nlm.nih.gov/pubmed/26785287
http://dx.doi.org/10.2217/fon.15.326

Ejemplares similares